Chronic Kidney Disease Stage 5 Clinical Trial
Official title:
Randomized Controlled Trial of a Low-Protein Diet (LPD) With Low-Protein (LP) Foods Versus a LPD Without LP Foods in Patients With Chronic Kidney Disease (CKD): Efficacy and Feasibility Study
The KDOQI 2020 - Clinical practice guideline for nutrition in chronic kidney disease (CKD) -recommends protein restriction to reduce the risk of end-stage renal disease/death and improve quality of life, a low protein diet providing 0.55-0.60g dietary protein/ kg body weight/day is recommended. FLAVIS® is a product line of hypoprotein foods specially developed for the treatment of CKD.The use of low-protein foods may facilitate the achievement of nutritional goals in terms of protein intake and help patients to follow a low-protein diet.
Status | Recruiting |
Enrollment | 244 |
Est. completion date | September 15, 2025 |
Est. primary completion date | September 15, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - CKD patient stage 3b-5 (<45 ml/min/1.73 m² estimated by CKD-EPI formula) and not on dialysis, - With a good nutritional status (i.e., absence of malnutrition according to albumin, pre-albumine, BMI and no clinical and paraclinical criteria of malnutrition), - Above 1g protein/ kg bw (ideal body weight), - LPD-naïve patient, - Motivated to LPD introduction (ensure during screening phase patient willingness to modify diet habits with counselling accurate follow-up), - Available to attend the visits planned by the protocol and able to complete the data collection documents (diet record and self-administered questionnaires), - Subject affiliated to a health insurance system or is a beneficiary (art. L.1121-11, Code of Public Health, France), - Having given their informed written consent regarding its participation to the protocol. Exclusion Criteria: - Patient for whom dialysis or transplantation is planned/expected within the next 12 months - Known allergic reactions to the ingredients present in FLAVIS products (milk, eggs, soy, nut), - Diabetis mellitus (Type I and 2 defined as fasted glycemia > 1 .26 g/L or HbA1C >7% or anti-diabetic treatment), - Active cancer, - Psychiatric disorders or inability to follow the protocol, - Evidence of any active infectious or inflammatory diseases, - Inability to provide blood samples (poor venous capital), - Inability to perform correct 24-hours urine collection, - Any change of the chronic medication within 1 month before screening, - Presence of any significant medical finding or significant history such as uncontrolled systemic diseases that may impact the safety, the interpretation of the results and/or the participation of the subject in the study according to the opinion of the investigator, - Simultaneous participation in another clinical trial or subject still within the exclusion period of a previous clinical trial. - Vulnerable subjects (art. L. 1121-5 à 8 et L. 1122-1-2, Code of Public Health, France) are also excluded from the clinical trial. |
Country | Name | City | State |
---|---|---|---|
France | Cabinet médical du Dr Magnant | Aix-en-Provence | |
France | CHU Besançon | Besançon | |
France | Maison du Rein | Bordeaux | |
France | CH Chalon | Chalon-sur-Saône | |
France | CHU Gabriel Montpied | Clermont-Ferrand | |
France | CH Le Mans | Le Mans | |
France | Hospices Civiles de Lyon | Lyon | |
France | CH Mâcon | Mâcon | |
France | Hôpital la conception | Marseille | |
France | AURA Paris | Paris | |
France | Tenon hospital -APHP | Paris | |
France | Hôpital Nord-Ouest | Villefranche-sur-Saône |
Lead Sponsor | Collaborator |
---|---|
Dr. Schär AG / SPA | Slb Pharma |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effectiveness in terms of protein intake of a LPD with LP foods (FLAVIS products) compared to standard products (LPD without consumption of LP foods) | Maroni formula : (Measurement of urea in urine + ([patient weight]*0.031))*6.25 | 12 month | |
Secondary | Protein intake during the 12 months follow-up | Maroni formula: (Measurement of urea in urine + ([patient weight]*0.031))*6.25 | 1 month, 3 month, 6 month and 9 month | |
Secondary | Dietary adherence | 3-day dietary record correlated to a 24-hour urine collection | baseline, 1 month, 3 month, 6 month and 12 month | |
Secondary | Dietary compliance for products under study | quantities consumed of FLAVIS products. | monthly up to 12 months | |
Secondary | Effects of the LPD on BMI | weight and height will be combined to report BMI in kg/m^2 | baseline, 1 month, 3 month, 6 month and 12 month | |
Secondary | Effects of the LPD on weight | Weight in kg | baseline, 1 month, 3 month, 6 month and 12 month | |
Secondary | Effects of the LPD on body composition: water | Water in litres | baseline, 1 month, 3 month, 6 month and 12 month | |
Secondary | Effects of the LPD on body composition: muscles | Muscles in Kg | baseline, 1 month, 3 month, 6 month and 12 month | |
Secondary | Effects of the LPD on body composition: body protein content | Body protein content in Kg | baseline, 1 month, 3 month, 6 month and 12 month | |
Secondary | Effects of the LPD on Blood | Blood Chemistry | baseline, 1 month, 3 month, 6 month, 9 month and 12 month | |
Secondary | Effects of the LPD on Urine | Urine Chemistry | baseline, 1 month, 3 month, 6 month, 9 month and 12 month | |
Secondary | Incidence of Adverse Events [Safety of the LPD] | Questioning and a clinical examination; 4-point Likert scale. | 3 month, 6 month and 12 month | |
Secondary | Patient quality of life | SF-36 questionnaire score which from 0 to 100 | baseline, 3 month, 6 month and 12 month | |
Secondary | Patient satisfaction with LPD | Auto-questionnaire, open questions | 3 month, 6 month and 12 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03539861 -
Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients
|
N/A | |
Recruiting |
NCT03311321 -
Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients
|
N/A | |
Completed |
NCT05630729 -
Living With CKD: An E-Learning Platform for Adolescents With CKD About the Disease and Its Management
|
N/A | |
Withdrawn |
NCT03998917 -
Pathophysiological Characterization of the Neuromuscular Function of a Population With Multiple Comorbidities Suffering From Chronic Renal Failure in Pre-dialysis.
|
||
Completed |
NCT04207203 -
Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study
|
N/A | |
Recruiting |
NCT01591876 -
Exercise and Vascular Function in Haemodialysis Patients
|
Phase 2 | |
Not yet recruiting |
NCT04608422 -
Bioeletric Stimulation in Patients With Chronic Kidney Failure
|
N/A | |
Completed |
NCT03868371 -
Acute Changes in the Mineral Metabolism After a High Phosphorous Containing Meal in Dialysis Patients
|
N/A | |
Active, not recruiting |
NCT05225454 -
The Life Style Patterns and the Development Trend of Chronic Diseases in Healthy and Sub-healthy Groups Were Analyzed by Using Data-mining Techniques
|
||
Completed |
NCT03459807 -
Blood Pressure Lowering in Dialysis (BOLD) Trial
|
Phase 2 | |
Not yet recruiting |
NCT03005847 -
The Effect of Fermented Papaya Preparation on Patients With Chronic Kidney Disease Under Dialysis Receiving Intravenous Iron
|
N/A | |
Recruiting |
NCT05726526 -
CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients
|
N/A | |
Recruiting |
NCT04330807 -
Physiopathology of Neuromuscular Function Related to Fatigue in Chronic Renal Disease
|
N/A | |
Active, not recruiting |
NCT02858778 -
Timing of Acute Palliative Care Consultation in Critically Ill Patients
|
N/A | |
Active, not recruiting |
NCT04034966 -
Utility of Telemedicine in the Follow-Up of Patients in Peritoneal Dialysis
|
N/A | |
Completed |
NCT04012957 -
Desidustat in the Treatment of Anemia in CKD
|
Phase 3 | |
Terminated |
NCT02039167 -
Left Atrial Appendage Occlusion vs. Usual Care in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease
|
N/A | |
Completed |
NCT01764854 -
Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis
|
Phase 2 | |
Active, not recruiting |
NCT06037265 -
PR-0164 First in Human Clinical Trial of the PAVmed PortIO Intraosseous Infusion System
|
N/A | |
Active, not recruiting |
NCT05350098 -
Efficacy of Plant-protein Diets in Patients With Chronic Kidney Disease
|
N/A |